No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review.
No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review.
复制标题
没有任何行动是没有副作用的：药物不良反应和错过的抗结核治疗剂量，范围审查。
DOI：
10.1111/bcp.15908
复制
发表时间：
2024
影响因子：
3.4
通讯作者：
Dixon EG
中科院分区：
文献类型：
--
作者：
Dixon EG
抗结核（抗TB）治疗失败的一个关键原因是漏服剂量（未服用药物的情况）。药物不良反应（ADR）是漏服剂量的1个原因，但全球证据表明，其对漏服剂量的相对贡献与。其他原因、ADR导致的漏服剂量模式以及与漏服剂量相关的特定ADR尚未得到评价。我们试图通过范围审查来解决这些问题。方法MEDLINE，Embase和Web of Science于2021年11月3日使用活动性结核病，漏服剂量和治疗挑战的术语进行检索。对报告ADR和漏服剂量数据的研究进行了检查（PROSPERO：CRD 42022295209）。结果分析确定了108项合格研究：88/108（81%）研究与ADR相关，漏服剂量增加; 33/61（54%）记录漏服剂量原因的研究将ADR作为主要原因。没有研究检查由于ADR而漏服药物的模式; 41/108（38%）研究检查了68种ADR（跨越15个器官系统）与漏服药物之间的关联。药物敏感性测试概况以及漏服剂量是否来自患者、医疗保健专业人员或两者的细微差别。结论有大量证据表明，ADR是漏服抗结核治疗剂量的关键驱动因素。一些论文检查了特定的ADR，但没有一篇评价了ADR导致的漏服剂量模式，表明存在知识缺陷。了解为什么剂量都是和没有错过是至关重要的，在提供有针对性的干预措施，以改善治疗结果。
AimsA key reason for the failure of antituberculosis (anti‐TB) treatment is missed doses (instances where medication is not taken). Adverse drug reactions (ADRs) are 1 cause of missed doses, but the global evidence, their relative contribution to missed dosesvs. other causes, the patterns of missed doses due to ADRs and the specific ADRs associated with missed doses have not been appraised. We sought to address these questions through a scoping review.MethodsMEDLINE, Embase and Web of Science were searched on 3 November 2021 using terms around active TB, missed doses and treatment challenges. Studies reporting both ADR and missed dose data were examined (PROSPERO: CRD42022295209).ResultsSearches identified 108 eligible studies: 88/108 (81%) studies associated ADRs with an increase in missed doses; 33/61 (54%) studies documenting the reasons for missed doses gave ADRs as a primary reason. No studies examined patterns of missed doses due to ADRs; 41/108 (38%) studies examined associations between 68 types of ADR (across 15 organ systems) and missed doses. Nuance around ADR‐missed doses relations regarding drug susceptibility testing profile and whether the missed doses originated from the patient, healthcare professionals, or both were found.ConclusionThere is extensive evidence that ADRs are a key driver for missed doses of anti‐TB treatment. Some papers examined specific ADRs and none evaluated the patterns of missed doses due to ADRs, demonstrating a knowledge deficit. Knowing why doses both are and are not missed is essential in providing targeted interventions to improve treatment outcomes.